Pramipexole in treatment-resistant depression: a 16-week naturalistic study

Autor:	Lorenzo Lattanzi, Annalisa Bassi, Marianna Abelli, Stefano Pini, A. Gemignani, Liliana Dell'Osso, Giovanni B. Cassano, Paola Rucci, Giulia Battistini, Patricia R. Houck, Paolo Cassano
Rok vydání:	2002
Předmět:	medicine.medical_specialty Pramipexole medicine.medical_treatment medicine.disease Psychiatry and Mental health Electroconvulsive therapy Tolerability Internal medicine medicine Clinical Global Impression medicine.symptom Adverse effect Psychology Psychiatry Major depressive episode Treatment-resistant depression Biological Psychiatry Depression (differential diagnoses) medicine.drug
Zdroj:	Bipolar Disorders. 4:307-314
ISSN:	1398-5647
DOI:	10.1034/j.1399-5618.2002.01171.x
Popis:	Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002: 4: 307–314. © Blackwell Munksgaard 2002 Objective: To assess the antidepressant efficacy and tolerability of adjunctive pramipexole, a D2–D3 dopamine agonist, in patients with drug-resistant depression. Methods: The study sample consisted of in-patients with major depressive episode, according to the DSM-IV, and drug resistance. Pramipexole was added to antidepressant treatment with TCA or SSRI, at increasing doses from 0.375 to 1.0 mg/day. Two independent response criteria were adopted: a >50% reduction of the Montgomery–Asberg Depressive Rating Scale (MADRS) total score and a score of 1 or 2 on the Clinical Global Impression scale (CGI-I) at endpoint. Side-effects were assessed by the Dosage Record Treatment Emergent Symptom Scale (DOTES). Results: Thirty-seven patients were enrolled. Of these, 16 had unipolar depression and 21 had bipolar depression. Six patients dropped out in the first week. Of the 31 patients included in the analyses, 19 completed the 16-week follow-up. Mean maximal dose of pramipexole was 0.95 mg/day. Mean scores on MADRS decreased from 33.3 ± 8.4 at baseline to 13.9 ± 11.5 at endpoint (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::483ad64d7f94e30f8a56e776c1565f0b https://doi.org/10.1034/j.1399-5618.2002.01171.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.